See What HealthDay Can Do For You
Contact Us

Meta-Analysis Confirms miR-21 Expression Laryngeal CA Link

High miR-21 expression seen in laryngeal cancer versus non-neoplasm tissue

laboratory worker

TUESDAY, Dec. 22, 2015 (HealthDay News) -- Expression of miR-21 is associated with laryngeal carcinoma, with high expression related to increased laryngeal cancer risk, according to a meta-analysis published online Dec. 12 in the Journal of Evidence-Based Medicine.

Peng Zhou, M.D., from the West China Hospital at Sichuan University, and colleagues conducted a meta-analysis to examine the expression and clinical significance of miR-21 in tissues of laryngeal carcinoma. Data were reviewed from four studies with 160 cases.

The researchers observed no significant between-study heterogeneity. Meta-analyses showed that there was high miR-21 expression in laryngeal cancer versus non-neoplasm tissue (odds ratio, 4.47; P = 0.02). Expression of miR-21 between TMN I-II and TMN III-IV was reported in only one study.

"In conclusion, the expression of miR-21 correlative laryngeal carcinoma is confirmed. It suggests that high expression of miR-21 may be related with laryngeal cancer risk," the authors write. "The miR-21 expression level might be an important biological marker of laryngeal cancer diagnosis. Nonetheless, large and well-designed prospective studies should be conducted to confirm these findings before miR-21 can be implemented into routine clinical management."

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.